Lumosity, the brain training program from Lumos Labs, improved overall cognition in healthy adults in a large randomized clinical trial, according to results from the BRIGHT-Mind study. The findings are scheduled to be presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston on November 18, 2026. The study enrolled 801 adults aged 25 to 80 who trained at home for 12 weeks, either with Lumosity or with a comparison program of educational videos. Among the 677 participants in the primary analysis, those who trained with Lumosity improved more on a separate 12-test cognitive battery.
The comparison design was meant to address a common objection to brain training. The control group also spent time each day on a mentally engaging computer activity, and the cognitive tests used were ones participants had never practiced. That structure helps separate any effect of the training itself from general engagement or expectations. The researchers said the cognitive benefit was similar across ages 25 to 80.
Participants also rated their own changes. On the Patient Global Impression of Improvement, 70% of the Lumosity group reported better concentration, memory and clear thinking, compared with 46% of the comparison group. Lumosity participants also reported greater improvement in daily functioning across work or school, social life and home responsibilities. Training took about 15 to 25 minutes a day, at least five days a week, and 83.6% of those assigned to Lumosity completed at least 13 hours over the 12 weeks.
A subgroup had MRI scans before and after the study. Among 220 evaluable participants, the brain-predicted age difference shifted about 1.5 years more favorably with Lumosity than with the comparison program in those aged 60 to 80. In older participants, the brain's fluid-filled ventricles enlarged less with Lumosity, and cortical thickness was better maintained in regions tied to attention and cognitive control. Kelly MacNiven, a research scientist and study co-author, said the brain-age, ventricle and cortical-thickness results in participants 60 and older told a consistent story.
The trial enrolled healthy adults, so it does not show whether these effects apply to people with cognitive impairment or other neurological or psychiatric conditions. It ran for only 12 weeks, leaving open how long any benefit lasts with continued training or after stopping. The MRI brain-age analysis was prespecified, while the detailed ventricle and cortical findings and the participant-reported outcomes were exploratory and point toward further study.